of Inflammation Resolvins D1 and E1 To Promote Resolution Stimulated by Leukotrienes Is Reduced by Conjunctival Goblet Cell Secretion

The conjunctiva is a mucous membrane that covers the sclera and lines the inside of the eyelids. Throughout the conjunctiva are goblet cells that secrete mucins to protect the eye. Chronic inflammatory diseases such as allergic conjunctivitis and early dry eye lead to increased goblet cell mucin secretion into tears and ocular surface disease. The purpose of this study was to determine the actions of the inflammatory mediators, the leukotrienes and the proresolution resolvins, on secretion from cultured rat and human conjunctival goblet cells. We found that both cysteinyl leukotriene (CysLT) receptors, CysLT 1 and CysLT 2, were present in rat conjunctiva and in rat and human cultured conjunctival goblet cells. All leukotrienes LTB 4 , LTC 4 , LTD 4 , and LTE 4 , as well as PGD 2 , stimulated goblet cell secretion in rat goblet cells. LTD 4 and LTE 4 increased the intracellular Ca 2+ concentration ([Ca 2+ ] i ), and LTD 4 activated ERK1/2. The CysLT 1 receptor antagonist MK571 significantly decreased LTD 4 -stimulated rat goblet cell secretion and the increase in [Ca 2+ ] i . Resolvins D1 (RvD1) and E1 (RvE1) completely reduced LTD 4 -stimulated goblet cell secretion in cultured rat goblet cells. LTD 4 -induced secretion from human goblet cells was blocked by RvD1. RvD1 and RvE1 prevented LTD 4 - and LTE 4 stimulated increases in [Ca 2+ ] i , as well as LTD 4 activation of ERK1/2. We conclude that cysteinyl leukotrienes stimulate conjunctival goblet cell mucous secretion with LTD 4 using the CysLT 1 receptor. Stimulated secretion is terminated by preventing the increase in [Ca 2+ ] i and activation of ERK1/2 by RvD1 and RvE1. The Journal of Immunology , 2011, 186: 4455–4466.

[1]  J. Zieske,et al.  Immunolocalization of muscarinic and VIP receptor subtypes and their role in stimulating goblet cell secretion. , 1999, Investigative ophthalmology & visual science.

[2]  C. Serhan Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. , 2007, Annual review of immunology.

[3]  C. Serhan,et al.  Resolvin D1 binds human phagocytes with evidence for proresolving receptors , 2010, Proceedings of the National Academy of Sciences.

[4]  C. Serhan,et al.  Resolvins , 2002, The Journal of experimental medicine.

[5]  C. Serhan,et al.  An endogenous regulator of inflammation, resolvin E1, modulates osteoclast differentiation and bone resorption , 2008, British journal of pharmacology.

[6]  M. Toner,et al.  Rapid Appearance of Resolvin Precursors in Inflammatory Exudates: Novel Mechanisms in Resolution1 , 2008, The Journal of Immunology.

[7]  Jeffrey A. Bair,et al.  Stimulatory role of PKCalpha in extracellular regulated kinase 1/2 pathway in conjunctival goblet cell proliferation. , 2009, Investigative ophthalmology & visual science.

[8]  J. Uddin,et al.  Resolvin D1 and Its Aspirin-triggered 17R Epimer , 2007, Journal of Biological Chemistry.

[9]  T. Ishizuka,et al.  Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma. , 2008, Biochemical and biophysical research communications.

[10]  R. Hodges,et al.  Isolation and characterization of cultured human conjunctival goblet cells. , 2003, Investigative ophthalmology & visual science.

[11]  B. Jessen,et al.  Corneal Neovascularization and Ocular Irritancy Responses in Dogs Following Topical Ocular Administration of an EP4-Prostaglandin E2 Agonist , 2009, Toxicologic pathology.

[12]  J. Gu,et al.  ERK/p44p42 mitogen-activated protein kinase mediates EGF-stimulated proliferation of conjunctival goblet cells in culture. , 2008, Investigative ophthalmology & visual science.

[13]  D. Dartt Control of mucin production by ocular surface epithelial cells. , 2004, Experimental eye research.

[14]  A. Sher,et al.  Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1 , 2005, The Journal of experimental medicine.

[15]  Lois E. H. Smith,et al.  Increased dietary intake of ω-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis , 2007, Nature Medicine.

[16]  N. Nieto,et al.  Dietary polyunsaturated fatty acids improve histological and biochemical alterations in rats with experimental ulcerative colitis. , 2002, The Journal of nutrition.

[17]  R. Dana,et al.  Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators. , 2009, Investigative ophthalmology & visual science.

[18]  B. Levy,et al.  Resolvin E1 regulates interleukin 23, interferon-γ and lipoxin A4 to promote the resolution of allergic airway inflammation , 2008, Nature Immunology.

[19]  C. Labat,et al.  A second cysteinyl leukotriene receptor in human lung. , 1992, The Journal of pharmacology and experimental therapeutics.

[20]  Santa Jeremy Ono,et al.  Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. , 2005, The Journal of allergy and clinical immunology.

[21]  G. Rasi,et al.  Montelukast, a leukotriene receptor antagonist, in vernal keratoconjunctivitis associated with asthma. , 2003, Archives of ophthalmology.

[22]  B. Levy,et al.  RvE1 protects from local inflammation and osteoclastmediated bone destruction in periodontitis , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  C. Clish,et al.  Novel Functional Sets of Lipid-Derived Mediators with Antiinflammatory Actions Generated from Omega-3 Fatty Acids via Cyclooxygenase 2–Nonsteroidal Antiinflammatory Drugs and Transcellular Processing , 2000, The Journal of experimental medicine.

[24]  C. Serhan,et al.  Resolvin E1 Receptor Activation Signals Phosphorylation and Phagocytosis* , 2009, The Journal of Biological Chemistry.

[25]  J. Gu,et al.  Role of neurotrophins and neurotrophin receptors in rat conjunctival goblet cell secretion and proliferation. , 2007, Investigative ophthalmology & visual science.

[26]  Christophe Baudouin,et al.  The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.

[27]  Heung-Man Lee,et al.  Up-regulation of MUC5AC and MUC5B mucin genes in chronic rhinosinusitis. , 2004, Archives of otolaryngology--head & neck surgery.

[28]  G. Scadding,et al.  Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. , 2002, The New England journal of medicine.

[29]  M. Stern,et al.  Ocular anti‐allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[30]  S. Paruchuri,et al.  Leukotriene E4–induced pulmonary inflammation is mediated by the P2Y12 receptor , 2009, The Journal of experimental medicine.

[31]  M. Parmentier,et al.  The C-terminal Nonapeptide of Mature Chemerin Activates the Chemerin Receptor with Low Nanomolar Potency* , 2004, Journal of Biological Chemistry.

[32]  Makoto Arita,et al.  Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  William Farley,et al.  Tear cytokine profiles in dysfunctional tear syndrome. , 2009, American journal of ophthalmology.

[34]  D. Woodward,et al.  Platelet-activating factor causes goblet cell depletion in the conjunctiva. , 1989, European journal of pharmacology.

[35]  C. Serhan Systems approach with inflammatory exudates uncovers novel anti-inflammatory and pro-resolving mediators. , 2008, Prostaglandins, leukotrienes, and essential fatty acids.

[36]  Charles N. Serhan,et al.  Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators , 2008, Nature Reviews Immunology.

[37]  B. Schultz,et al.  Pharmacology of ocular allergy , 2006, Current opinion in allergy and clinical immunology.

[38]  Guoxing Wang,et al.  Differences in goblet cell differentiation between Crohn's disease and ulcerative colitis. , 2009, Differentiation; research in biological diversity.

[39]  V. Capra Molecular and functional aspects of human cysteinyl leukotriene receptors. , 2004, Pharmacological research.

[40]  D. Zoukhri,et al.  Activation of mitogen-activated protein kinase by cholinergic agonists and EGF in human compared with rat cultured conjunctival goblet cells. , 2003, Investigative ophthalmology & visual science.

[41]  S. Dahlén,et al.  Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. , 1987, Science.

[42]  Carolyn G. Begley,et al.  The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.

[43]  J. Duffield,et al.  Resolvin D Series and Protectin D1 Mitigate Acute Kidney Injury1 , 2006, The Journal of Immunology.

[44]  D. Zoukhri,et al.  Cholinergic agonists transactivate EGFR and stimulate MAPK to induce goblet cell secretion. , 2003, American journal of physiology. Cell physiology.

[45]  D. Dartt,et al.  Development of conjunctival goblet cells and their neuroreceptor subtype expression. , 2000, Investigative ophthalmology & visual science.

[46]  D. Zoukhri,et al.  Regulation of conjunctival goblet cell secretion by Ca(2+)and protein kinase C. , 2000, Experimental eye research.

[47]  C. D. Richardson,et al.  5-lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. , 1993, European journal of biochemistry.

[48]  D. Rogers The airway goblet cell. , 2003, The international journal of biochemistry & cell biology.